SCHEMBL14224908

SCHEMBL14224908

NC(=O)c1cc(-c2csc(-c3cccc(NC(=O)CN4CCOCC4)c3)n2)c[nH]1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 2/20 0.54
ALDH1A1 P00352 8/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
MAPT P10636 4/20 0.48
KMT2A Q03164 2/20 0.48
MAPK1 P28482 2/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
MAP4K4 O95819 1/20 0.47
HTT P42858 2/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 3/20 0.46
MGLL Q99685 1/20 0.45
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
CDC25C P30307 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14315470 0.91 MGLL (0.53) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14224957 0.90 JAK3 (0.51) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14150274 0.90 JAK3 (0.51) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14224904 0.89 JAK3 (0.51) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14318313 0.89 JAK3 (0.51) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
Hydrochloric Acid SCHEMBL14150343 0.89 JAK3 (0.51) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14224903 0.88 JAK3 (0.50) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A
SCHEMBL14315469 0.85 POLB (0.49) ALDH1A1SMN1; SMN2MAPTKMT2APOLB
SCHEMBL14318345 0.83 POLB (0.49) ALDH1A1SMN1; SMN2MAPTKMT2AMAPK1
SCHEMBL16404007 0.83 MAPT (0.56) JAK3ALDH1A1SMN1; SMN2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2718290-B1 COMPOSITIONS AND METHODS FOR MODULATING A KINASE CLEVEXEL PHARMA (FR) 2016-05-04 EP disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
US-8937065-B2 Compositions and methods for modulating a kinase CLEVEXEL PHARMA (FR) 2015-01-20 US disclosed
WO-2012172438-A9 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2013-02-07 WO disclosed
WO-2012172438-A2 COMPOSITIONS AND METHODS FOR MODULATING A KINASE DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-12-20 WO disclosed
US-20120316148-A1 Compositions and Methods for Modulating a Kinase DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120316148-A1 Compositions and Methods for Modulating a Kinase PRKCH, MAP3K2, MAP3K6 JAK3 409/4885ALDH1A1 4672/4885SMN1; SMN2 3668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.